Temodal gains additional use

The licensed indications for the antineoplastic agent Temodal (temozolomide) have been extended to include the treatment of patients with newly diagnosed glioblastoma multiforme.

Temodal is administered orally together with focal radiotherapy, followed by up to six cycles as monotherapy.

A clinical trial involving 573 patients with newly diagnosed glioblastoma multiforme randomised to receive temozolomide plus radiotherapy or radiotherapy alone showed a significant improvement in survival in the radiotherapy plus temozolomide group compared with the radiotherapy-only group.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Herts AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Antidiabetic Agents, Use in Renal Impairment

Antidiabetic Agents, Use in Renal Impairment

Dosing of diabetes drugs in patients with renal impairment.

Insulin Delivery Devices

Insulin Delivery Devices

Features and compatibility of insulin pens.

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.